The Australian market has shown resilience with the ASX200 closing up 0.58% following a rate cut by the RBA, and the IT sector leading gains with a 2.3% increase, indicating positive sentiment towards technology stocks amidst broader economic adjustments. In this environment, identifying high growth tech stocks like Life360 and others involves looking for companies that can leverage favorable sector dynamics and demonstrate strong potential for innovation and expansion in a shifting economic landscape.
Top 10 High Growth Tech Companies In Australia
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Gratifii | 42.14% | 113.99% | ★★★★★★ |
| Pro Medicus | 22.19% | 23.49% | ★★★★★★ |
| BlinkLab | 65.54% | 64.35% | ★★★★★★ |
| WiseTech Global | 20.14% | 25.01% | ★★★★★★ |
| Pointerra | 50.42% | 159.12% | ★★★★★☆ |
| Wrkr | 57.01% | 116.83% | ★★★★★★ |
| AVA Risk Group | 29.15% | 108.15% | ★★★★★★ |
| Echo IQ | 61.50% | 65.86% | ★★★★★★ |
| Immutep | 70.42% | 42.39% | ★★★★★☆ |
| SiteMinder | 19.93% | 69.52% | ★★★★★☆ |
Click here to see the full list of 48 stocks from our ASX High Growth Tech and AI Stocks screener.
Let's explore several standout options from the results in the screener.
Life360 (ASX:360)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Life360, Inc. operates a technology platform that helps locate people, pets, and things across various regions globally, with a market capitalization of A$7.12 billion.
Operations: The company generates revenue primarily through its software and programming segment, amounting to $396.88 million. The platform's focus on location services spans North America, Europe, the Middle East, Africa, and other international markets.
Life360 has demonstrated a robust turnaround with its Q1 2025 earnings, posting a revenue of USD 103.62 million and transitioning from a net loss to a net income of USD 4.38 million. This performance is underscored by an annual revenue growth forecast at 16.1%, significantly outpacing the Australian market's average of 5.5%. The strategic partnership with Aura, involving a $25 million investment and exclusive rights for bundled sales, could amplify Life360's market channels effectively. Additionally, the appointment of Vari Bindra as CISO aligns with its strategic emphasis on security and privacy, essential in enhancing consumer trust in technology dedicated to family safety and connection.
- Dive into the specifics of Life360 here with our thorough health report.
Explore historical data to track Life360's performance over time in our Past section.
Codan (ASX:CDA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Codan Limited is a technology solutions provider serving United Nations organizations, security and military groups, government departments, individuals, and small-scale miners with a market cap of A$3.14 billion.
Operations: The company generates revenue primarily from its Communications and Metal Detection segments, with Communications accounting for A$360.27 million and Metal Detection contributing A$224.90 million.
Codan has showcased a notable performance in the tech sector, with its half-year sales jumping to AUD 305.62 million from AUD 265.92 million, reflecting a robust growth trajectory. This increase is paired with a net income rise to AUD 46.04 million, up from AUD 38.04 million, outpacing the electronic industry's average earnings growth of 8.3%. Importantly, Codan's commitment to innovation is evident in its R&D investments which are critical for maintaining its competitive edge in rapidly evolving technological landscapes. The company's strategic dividend increase also signals confidence in sustained financial health and shareholder value enhancement.
- Delve into the full analysis health report here for a deeper understanding of Codan.
Evaluate Codan's historical performance by accessing our past performance report.
Immutep (ASX:IMM)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Immutep Limited is a late-stage biotechnology company focused on developing innovative LAG-3 related immunotherapies for cancer and autoimmune diseases, with a market capitalization of approximately A$430.81 million.
Operations: The company generates revenue primarily from its immunotherapy segment, amounting to approximately A$4.88 million.
Immutep, an emerging name in the biotech sector, is steering towards profitability with expected earnings growth of 42.39% annually over the next three years. This growth trajectory is underscored by a remarkable annual revenue increase forecast at 70.4%, significantly outpacing the broader Australian market's average of 5.5%. Recent trials like INSIGHT-003 have demonstrated promising results, achieving a 60.8% response rate in advanced lung cancer treatments using Immutep's eftilagimod alpha in combination therapies. These developments not only highlight Immutep’s potential in addressing unmet medical needs but also position it as a notable entity within high-growth biotechnological advancements.
- Click to explore a detailed breakdown of our findings in Immutep's health report.
Gain insights into Immutep's historical performance by reviewing our past performance report.
Next Steps
- Explore the 48 names from our ASX High Growth Tech and AI Stocks screener here.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Immutep might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com